Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Olaparib vs Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT05295589Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Planned start Jun 2022; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05295589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295589.